<DOC>
	<DOCNO>NCT00557661</DOCNO>
	<brief_summary>An open-label study design determine safety , tolerability pharmacodynamics CD-NP infusion heart failure patient .</brief_summary>
	<brief_title>Safety Study CD-NP Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Key Male female â‰¥18 year age diagnose NYHA class III IV heart failure last six month Female patient must postmenopausal surgically sterile Diagnosed heart failure leave ventricular ejection fraction &lt; 40 % obtain within prior 6 month least one symptom sign volume overload Key Women pregnant , breastfeed childbearing potential Clinically unstable patient Major surgical procedure within 30 day entry Febrile temp &gt; 100 degree F ) Symptomatic carotid disease , critical carotid stenosis , stroke within 3 month prior study entry Currently IV vasoactive support ( e.g. , heart transplant candidate ) History unexplained syncope within past 3 month History organ transplantation Comorbidities clinically significant cardiac valvular stenosis , aortic valvular disease , restrictive cardiomyopathy , hypertrophic obstructive cardiomyopathy , constrictive pericarditis , primary pulmonary hypertension , infiltrative disease , uncorrected congenital heart disease , acute coronary syndrome , restrictive heart failure , condition , opinion Investigator , would prevent patient 's participation study . Participation clinical trial investigational therapy device within 30 day prior randomization . Treatment nesiritide within 14 day prior dose . Inability effectively communicate study personnel .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>CD-NP</keyword>
</DOC>